-
Abstract Number: L01
Outcomes of COVID-19 Infection in Patients with Rheumatic Diseases in a Multicenter Healthcare System: A Comparative Cohort Study
-
Abstract Number: L02
Risk Mitigating Behavior in People with Rheumatic Diseases or Psoriasis During the COVID-19 Pandemic Differ by Immunosuppressant Treatment Type: A Patient survey Study
-
Abstract Number: L03
Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
-
Abstract Number: L04
Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program
-
Abstract Number: L05
DMARD Changes for Patients with Rheumatoid Arthritis in the US During the First Three Months of the COVID-19 Pandemic
-
Abstract Number: L06
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis
-
Abstract Number: L07
Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial
-
Abstract Number: L08
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)
-
Abstract Number: L09
A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)
-
Abstract Number: L10
Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734
-
Abstract Number: L11
Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
-
Abstract Number: PP01
Impacting Change Through Facilitation and Advocacy for Lupus
-
Abstract Number: PP02
Low- and Hi-Tech Tools for Enhancing Patient-Hospital Care Team Communication in the Context of Rare Disease
-
Abstract Number: PP03
Connecting with Rheumatology Professionals and Thought Leaders Inspired the Creation of a New Program Focused on Relapsing Polychondritis (“RP”), a Rare Rheumatic Disease: Participating at ACR Annual Meetings Has Provided Exceptional Opportunities to Learn and Build Relationships
-
Abstract Number: PP04
My Multidisciplinary Healthcare Team and Patient Advocacy Groups Saved My Life
- 1
- 2
- 3
- …
- 139
- Next Page »